Inhibition of PI3K and ERK pathway signalling was demonstrated in solid tumours, and prolonged stable disease has been observed in patients with cancers including non-Hodgkin’s lymphoma and non-small cell lung cancer. The gene discussed is PIK3CD; the disease is non-Hodgkin lymphoma.